Mode
Text Size
Log in / Sign up
N/A N=69 Randomized Single-blind Prevention

Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD

PTSD

Enrolled (actual)
69
Serious AEs
2.9%
Results posted
Jul 2024
Primary outcome: Primary: Change in Clinician-Administered PTSD Scale for DSM-5 — 38.39; 35.67; 27.15; 29.31 score on a scale — p=0.4154

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Trauma Management Therapy (Other); Exposure Therapy with Psychotherapy group (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Jul 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Clinician-Administered PTSD Scale for DSM-5
38.39; 35.67; 27.15; 29.31 0.4154
PRIMARY
Change in Social Adjustment Scale - Self-Report
2.855; 3.168; 2.953; 3.289 0.4636
PRIMARY
Change in PTSD Checklist for DSM-5
53.66; 56.92; 40.04; 46.53 0.735129
SECONDARY
Change in Aggression Questionnaire
59; 64.62; 58.92; 62.18 0.580
SECONDARY
Change in Interpersonal Trust Scale
60.21; 57.54; 63.33; 60.41 0.808

Summary

Social difficulties are serious and frequent complicating factors in the treatment of post-traumatic stress disorder (PTSD). To better understand how treatment of post-traumatic stress disorder impacts neural mechanisms of social cognition, the investigators are examining behavior and brain processes associated with response to Trauma Management Therapy. Understanding the behavioral and neural impact of psychotherapy may contribute to development of more effective treatments for PTSD.

Eligibility Criteria

Inclusion Criteria

  • Male and female veterans of all ethnicities
  • Meet diagnostic criteria for post-traumatic stress disorder (assessed by study staff)
  • Fluent in English
  • Able to see computer display clearly
  • Able to provide informed consent
  • Able to follow written or verbal instructions

Exclusion Criteria

  • history of seizures
  • history of stroke
  • Cushing's syndrome
  • history of moderate to severe traumatic brain injury
  • electroconvulsive therapy within 5 years
  • history of chemotherapy for cancer
  • contraindications to fMRI
  • pregnancy
  • diagnosis of schizophrenia, schizoaffective disorder, delusional disorder and/or organic psychosis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03449576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search